Back to News
Market Impact: 0.2
Oppenheimer Initiates Coverage of CorMedix at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of CorMedix (NASDAQ: CRMD) on September 23, 2026, with an Outperform recommendation. The positive analyst action supports sentiment toward the U.S.-based biopharmaceutical company, though the report provides no price target, earnings estimates, or clinical/commercial catalysts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CRMD0.50
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- Meta's standoff with Amazon over Muse could be a sign of things to come
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’